Results 171 to 180 of about 3,096 (189)
Some of the next articles are maybe not open access.

Enfortumab vedotin/insulin

Reactions Weekly, 2022
openaire   +1 more source

Pembrolizumab/enfortumab-vedotin

Reactions Weekly, 2023
openaire   +1 more source

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Tamas Masszi   +2 more
exaly  

Brentuximab vedotin improves outcomes

Nature Reviews Clinical Oncology, 2022
exaly  

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

New England Journal of Medicine, 2010
Anas Younes   +2 more
exaly  

Enfortumab vedotin is safe and effective

Nature Reviews Clinical Oncology, 2021
exaly  

Enfortumab-vedotin/pembrolizumab

Reactions Weekly, 2022
openaire   +2 more sources

Enfortumab-vedotin/pembrolizumab

Reactions Weekly, 2023
openaire   +1 more source

Enfortumab-vedotin/pembrolizumab

Reactions Weekly, 2021
openaire   +1 more source

Enfortumab vedotin

Reactions Weekly, 2019
openaire   +1 more source
urothelial carcinoma
urothelial cancer
bladder cancer
metastatic urothelial carcinoma
pembrolizumab
antibody-drug conjugate
nectin-4
antibody–drug conjugates
efficacy
previous   16  17  18  19  

Home - About - Disclaimer - Privacy